Abstract:
Objective To observe the changes of cardiac function related parameters in secondary hyperparathyroidism (SHPT) patients with maintenance hemodialysis (MHD) after using paricalcitol. Methods Forty SHPT patients with MHD in Huainan First People's Hospital from December 2019 to September 2020 were included. The clinical data, serum intact parathyroid hormone (iPTH), calcium, phosphorus and heart parameters before the treatment of paricalcitol were collected. The parameters included left ventricular ejection fraction (EF), left ventricular end-diastolic dimension (LVDd), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), left ventricular end systolic diameter (LVDs), left atrium diameter (LAD), left ventricular fractional shortening (FS), left ventricular mass (LVM) and left ventricular myocardial mass index (LVMI). The changes of the above-mentioned indicators before and after the medication were compared. Results Compared with baseline value, the serum iPTH of SHPT patients decreased significantly at 1, 3, and 6 months after using paricalcitol (P < 0.001), and serum calcium, phosphorus, calcium and phosphorus product levels were relatively stable. After 6 months of paricalcitol treatment, there were 21 SHPT patients (52.5%) whose iPTH decreased by greater than or equal to 50%, and 28 patients (70.0%) whose iPTH decreased by greater than or equal to 30%. After 6 months of paricalcitol treatment, LVMI, LVM, IVST, LVDd, LVPWT of 40 patients decreased significantly, and FS was increased (all P < 0.01). While LAD, LVDs and EF had no change (all P>0.05). The LAD, LVMI, LVM, IVST, LVDd, LVPWT of LVH group patients were also significantly lower than before, and FS was increased (all P < 0.01). While the non-LVH group patients showed no significant change (all P>0.05). Conclusion Paricalcitol can significantly reduce the serum iPTH level, treat SHPT patients with MHD effectively and has fewer adverse effects. It also could subside LVH or delay its progression.